96% Unpartnered Cancer Drugs Fail
Attrition High for Biotechs Without Partners; Worth It?
By Trista Morrison
Monday, March 5, 2012
A recent analysis from Deloitte Recap LLC showed that, when it comes to advancing a product from Phase I to approval, the odds are significantly better for biotechs who have a big pharma or big biotech partner.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.